Bioavailability Studies Submitted in NDAs or INDs – General Considerations
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
April 15, 2022
April 12, 2024
8946e94a-0bb7-41ed-a95c-e1fed34bf86b
Related Documents
Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies
Guidance DocumentSeptember 26, 2024Center for Drug Evaluation and Research
Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
Guidance DocumentJune 23, 2022Center for Drug Evaluation and Research
Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics: Guidance for Industry
Guidance DocumentJune 14, 2024Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox